DA-5204 / Dong-A - LARVOL DELTA

Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study. (PubMed, Medicine (Baltimore)) - "Combined therapy with PPI and DA-5204 has no additional effect on the endoscopic healing rate compared to PPI alone. However, it may be beneficial in resolving minimal change."

Clinical • Journal • Gastroenterology • Gastroesophageal Reflux Disease

EFFICACY OF DA-5204 FOR GASTROESOPAGEAL REFLUX DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY (DDW 2020) - "Combined therapy with PPI and DA-5204 had no difference in healing rate compared to PPI alone. However, our findings suggest that DA-5204 is more effective in subtle mucosal healing in reflux esophagitis"

Clinical

Efficacy of DA-5204 for gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study (APDW 2019) - "Our findings suggest that combined therapy with PPI and DA-5204 is more effective in treating GERD than PPI alone."

Clinical

Efficacy of DA-5204 (Stillen 2X(r)) for patients with Gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study (APDW 2019) - "Our findings suggest that combined therapy with PPI and DA-5204 is more effective in treating GERD than PPI alone."

Clinical

EFFICACY OF DA-5204 (STILLEN 2X®) FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY (UEGW 2019) - "Our findings suggest that combined therapy with PPI and DA-5204 is more effective in treating GERD than PPI alone."

Clinical

Efficacy of DA-5204 on Gastroesophageal Reflux Disease (clinicaltrials.gov) - P3; N=70; Completed; Sponsor: Seoul National University Hospital

Clinical • New P3 trial